- Home
- FIVN vs MLTX Comparison
FIVN vs MLTX Comparison
Compare FIVN & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIVN | MLTX |
|---|---|---|
| Founded | 2001 | 2021 |
| Country | | |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FIVN | MLTX |
|---|---|---|
| Price | $16.32 | $17.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $31.53 | $22.22 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.29 | N/A |
| Revenue Next Year | $9.40 | N/A |
| P/E Ratio | $44.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.70 | $5.95 |
| 52 Week High | $49.90 | $62.75 |
Technical Indicators
Market Signals| Indicator | FIVN | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 62.64 |
| Support Level | $15.70 | $15.27 |
| Resistance Level | $18.41 | $16.15 |
| Average True Range (ATR) | 1.04 | 0.81 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 21.29 | 97.13 |
Price Performance
Historical ComparisonAbout FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.